Rani Therapeutics Inc. (RANI)
Rani Therapeutics Statistics
Share Statistics
Rani Therapeutics has 57.54M shares outstanding. The number of shares has increased by 13.62% in one year.
| Shares Outstanding | 57.54M |
| Shares Change (YoY) | 13.62% |
| Shares Change (QoQ) | -0.24% |
| Owned by Institutions (%) | 13.24% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 12,694 |
| FTD / Avg. Volume | 1.49% |
Short Selling Information
The latest short interest is 2.34M, so 6.98% of the outstanding shares have been sold short.
| Short Interest | 2.34M |
| Short % of Shares Out | 6.98% |
| Short % of Float | 9.86% |
| Short Ratio (days to cover) | 12.33 |
Valuation Ratios
The PE ratio is -1.3 and the forward PE ratio is -1.55. Rani Therapeutics's PEG ratio is 0.06.
| PE Ratio | -1.3 |
| Forward PE | -1.55 |
| PS Ratio | 37.95 |
| Forward PS | 1.1 |
| PB Ratio | 19.58 |
| P/FCF Ratio | -1.09 |
| PEG Ratio | 0.06 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Rani Therapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.5, with a Debt / Equity ratio of 10.09.
| Current Ratio | 1.5 |
| Quick Ratio | 1.5 |
| Debt / Equity | 10.09 |
| Debt / EBITDA | -0.4 |
| Debt / FCF | -0.56 |
| Interest Coverage | -10.59 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $9,790.48 |
| Profits Per Employee | $-285,885.71 |
| Employee Count | 105 |
| Asset Turnover | 0.03 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -83.05% in the last 52 weeks. The beta is 0.24, so Rani Therapeutics's price volatility has been higher than the market average.
| Beta | 0.24 |
| 52-Week Price Change | -83.05% |
| 50-Day Moving Average | 1.35 |
| 200-Day Moving Average | 1.98 |
| Relative Strength Index (RSI) | 38.57 |
| Average Volume (20 Days) | 849,981 |
Income Statement
In the last 12 months, Rani Therapeutics had revenue of 1.03M and earned -30.02M in profits. Earnings per share was -1.05.
| Revenue | 1.03M |
| Gross Profit | 1.03M |
| Operating Income | -53.31M |
| Net Income | -30.02M |
| EBITDA | -50.52M |
| EBIT | -51.55M |
| Earnings Per Share (EPS) | -1.05 |
Balance Sheet
The company has 3.76M in cash and 20.1M in debt, giving a net cash position of -16.33M.
| Cash & Cash Equivalents | 3.76M |
| Total Debt | 20.1M |
| Net Cash | -16.33M |
| Retained Earnings | -102.91M |
| Total Assets | 36.63M |
| Working Capital | 9.85M |
Cash Flow
In the last 12 months, operating cash flow was -35.5M and capital expenditures -268K, giving a free cash flow of -35.76M.
| Operating Cash Flow | -35.5M |
| Capital Expenditures | -268K |
| Free Cash Flow | -35.76M |
| FCF Per Share | -1.26 |
Margins
Gross margin is 100%, with operating and profit margins of -5186.19% and -2920.04%.
| Gross Margin | 100% |
| Operating Margin | -5186.19% |
| Pretax Margin | -2920.04% |
| Profit Margin | -2920.04% |
| EBITDA Margin | -4914.69% |
| EBIT Margin | -5186.19% |
| FCF Margin | -3478.99% |
Dividends & Yields
RANI does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for RANI is $10, which is 825.9% higher than the current price. The consensus rating is "Buy".
| Price Target | $10 |
| Price Target Difference | 825.9% |
| Analyst Consensus | Buy |
| Analyst Count | 5 |
Scores
| Altman Z-Score | -7.08 |
| Piotroski F-Score | 2 |